Kingdon Capital Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Kingdon Capital Management’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,583,208	Closed	-$20.5M	–	65
2021 Q2	$20.5M	Sell	1,583,208 -165,000	-9%	-$2.1M	2.38%	12
2021 Q1	$22.7M	Buy	1,748,208 +80,000	+5%	+$1.16M	2.32%	11
2020 Q4	$23.1M	Buy	1,668,208 +60,000	+4%	+$873K	2.5%	11
2020 Q3	$23.7M	Buy	1,608,208 +257,400	+19%	+$3.73M	2.66%	12
2020 Q2	$22M	Buy	1,350,808 +888,128	+192%	+$14.2M	2%	12
2020 Q1	$6.71M	Buy	462,680 +419,011	+960%	+$7.39M	1.23%	30
2019 Q4	$885K	Buy	+43,669	New	+$402K	0.13%	50

Other funds holding AUPH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KPWS

Kestra Private Wealth Services Austin, Texas $9.1B AUM 32.09% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $23.5B AUM 33.24% 1-Year Est. Return

Kingdon Capital Management's AUPH Position: Q3 2021 in Review

Kingdon Capital Management sold out of Aurinia Pharmaceuticals (AUPH) in Q3 2021, closing a stake of 1,583,208 shares — an estimated $20.5M sold.

Kingdon Capital Management first reported a position in AUPH in Q4 2019 and held it in 7 quarters. The position peaked at $23.7M in Q3 2020. 167 funds tracked by Wall St. Rank hold AUPH as of Q3 2021.

Kingdon Capital Management reported no remaining Aurinia Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Kingdon Capital Management sold 1,583,208 Aurinia Pharmaceuticals shares in Q3 2021, an estimated $20.5M.
Kingdon Capital Management first reported a position in Aurinia Pharmaceuticals in Q4 2019 and held it in 7 quarters.
Kingdon Capital Management's Aurinia Pharmaceuticals position peaked at $23.7M in Q3 2020.
167 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2021.

Based on Kingdon Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.